Physician profile
Yvette Freeman
NPI 1821864208
$1,883.32
in general payments reported to CMS, 2019-2025
17 companies · $817 in 2025
The $817 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,066 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.24 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $310.78 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $283.06 | 2024-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $161.62 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $130.60 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $126.51 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $124.66 | 2024-2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $124.14 | 2024-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $111.60 | 2024-2025 | Veltassa |
| Amgen INC. | $95.84 | 2024-2025 | Krystexxa, Tavneos |
| Ani Pharmaceuticals, INC. | $82.42 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $70.11 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $66.90 | 2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $62.07 | 2024-2025 | |
| Ardelyx, INC. | $49.27 | 2024 | Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.32 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $21.60 | 2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $15.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.